+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 28 Actively Recruiting clinical trials

M

Actively Recruiting

Researchers are conducting a master protocol study to evaluate multiple independent pain interventions for chronic pain conditions, including osteoarthritis of the knee, chronic low back pain, and diabetic peripheral neuropathic pain. This phase 2, randomized, placebo-controlled trial aims to establish a framework for disease-state addenda and intervention-specific appendices to efficiently study different treatments as they become available. Participants are randomly assigned to receive one of several investigational drugs or a matching placebo. These drugs include LY3016859 administered intravenously and LY3556050, LY3526318, LY3857210, and LY4065967 administered orally. Each intervention-specific appendix operates independently within the overarching study structure, allowing evaluation of various treatments targeting different chronic pain conditions. During the study, participants undergo screening and are monitored for pain levels using specific scales. They maintain consistent use of non-drug pain therapies and discontinue other chronic pain medications except rescue medication. Researchers measure participant allocation to each intervention up to week 8. Safety is monitored through physical exams, ECGs, laboratory tests, and medical history assessments. The study is expected to be completed by April 2027.

Age: 18Years +All GendersPhase 2
64 locations
L

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the long-term effects of aleniglipron, an oral drug, in adults living with obesity or overweight and type 2 diabetes mellitus T2DM. This randomized, double-blind, placebo-controlled phase 3 study aims to assess the efficacy, safety, and tolerability of multiple doses of aleniglipron for chronic weight management in this population. Participants will be randomly assigned to receive either oral aleniglipron or a placebo once daily. The treatment period lasts for 76 weeks, during which participants will take the assigned medication regularly. The study includes several experimental arms receiving aleniglipron and one placebo arm to compare outcomes. During the study, participants will have assessments at baseline and week 76 to measure changes in body weight, waist circumference, HbA1c levels, blood pressure, triglycerides, and cholesterol. Researchers will track the percentage of participants achieving significant weight loss and HbA1c targets. Safety and tolerability will be monitored throughout the treatment period, with the total participation lasting approximately 76 weeks.

Age: 18Years - 79YearsAll GendersPhase 3
74 locations
R

Actively Recruiting

Researchers are studying the safety and effectiveness of RTN-001, a modified release drug, in adults aged 18 to 75 years with uncontrolled and resistant hypertension, defined as systolic blood pressure SBP of 135 mm Hg or higher and diastolic blood pressure DBP of 80 mm Hg or higher. This Phase 2b trial is randomized, double-blind, and involves multiple centers. The study includes three main periods Screening, Run-in, and Treatment. During the trial, about 280 eligible participants will be randomly assigned equally into four groups to receive one of three doses of RTN-001 15 mg, 30 mg, or 45 mg or a matching placebo. The treatment lasts for 12 weeks. After the treatment period ends, participants will have an off-treatment follow-up visit two weeks later to assess their condition. Participants will be involved in various assessments throughout the study, including blood pressure measurements taken at multiple time points during and after treatment. Researchers will monitor changes in systolic and diastolic blood pressure using office measurements, central blood pressure readings, and ambulatory monitoring. Safety and efficacy will be evaluated through these repeated measures, and adherence to the study drug will be tracked. The total participation includes screening, run-in, treatment, and follow-up visits spanning several months.

Age: 18Years - 75YearsAll GendersPhase 2
44 locations
R

Actively Recruiting

This trial is focused on adults aged 50 and older with mild to moderate Alzheimers disease. Researchers aim to evaluate the safety and tolerability of Zunveyl, a medication taken orally, during 12 weeks of routine use. The study also looks at how the drug affects neuropsychiatric symptoms and caregiver distress for these patients. Participants will take Zunveyl delayed-release tablets twice daily, starting with 5 mg from Weeks 1 to 4, then increasing to 10 mg twice daily from Weeks 5 to 12. This open-label, phase 4 study monitors participants throughout this 12-week treatment period to assess how well they tolerate the medication and to observe any side effects. During the study, participants and their caregivers will attend regular visits where assessments will be made including safety checks, neuropsychiatric evaluations using the Neuropsychiatric Inventory NPI-12, and measurements of caregiver distress. Researchers will track adverse events, treatment interruptions, dose reductions, and overall tolerability scores up to Week 17. The total participation lasts about 12 weeks with follow-up assessments to evaluate ongoing safety and effects.

Age: 50Years +All GendersPhase 4
22 locations
E

Actively Recruiting

Researchers are evaluating the drug TNX-102 SL to see if it helps treat adults with moderate to severe major depressive disorder MDD. This study aims to compare TNX-102 SL with a placebo to determine its effect on depression symptoms using a rating scale, and to assess the safety and medical issues participants may experience while taking the drug. Participants will take either 5.6 mg of TNX-102 SL two 2.8 mg tablets or matching placebo tablets every night at bedtime for six weeks. During the study, participants will visit the clinic every two weeks for checkups and tests to monitor their progress. Throughout the study, researchers will assess changes in depression severity using the MADRS score and other measures such as sleep disturbance and clinical impression scales. Safety and tolerability will also be monitored. Participation involves regular clinic visits over the six-week treatment period, with assessments occurring at baseline and every two weeks until the study concludes.

Age: 18Years +All GendersPhase 2
27 locations
E

Actively Recruiting

This research aims to evaluate the effectiveness and safety of North Star desiccated porcine thyroid extract tablets in adults with primary hypothyroidism, including Hashimotos Thyroiditis. The trial is a Phase 3, open-label, single-arm study conducted across multiple centers, focusing on treatment outcomes for this condition. Participants will receive North Star desiccated porcine thyroid extract tablets as the study treatment. The study monitors thyroid-stimulating hormone TSH levels to assess whether they remain within the normal range at 24 weeks and at prior post-baseline visits without abnormal readings. Safety evaluations include tracking adverse events, serious adverse events, laboratory tests, ECGs, and physical exams through 30 weeks. During the study, participants will be closely monitored with regular assessments of thyroid function and safety measures. Researchers will collect clinical data, lab results, and examine physical health to understand treatment impact. The total follow-up period extends to at least 30 weeks, allowing detailed observation of treatment effects and potential side effects in adults aged 18 to 75 years with stable hypothyroidism management.

Age: 18Years - 75YearsAll GendersPhase 3
25 locations
R

Actively Recruiting

Researchers are evaluating treatments for people diagnosed with Stage I HER2-positive invasive breast cancer. This study compares two combinations of HER2-targeted therapies given after surgery to see how well they work and their side effects. The study focuses on whether trastuzumab-emtansine followed by subcutaneous trastuzumab has fewer side effects than the standard treatment of paclitaxel plus trastuzumab. It also aims to learn about long-term benefits and disease-free survival. Participants will be randomly assigned to one of two treatment groups. One group receives intravenous trastuzumab-emtansine every 3 weeks for 18 weeks, followed by subcutaneous trastuzumab every 3 weeks for 33 weeks. The other group receives weekly intravenous paclitaxel for 12 weeks along with subcutaneous trastuzumab every 3 weeks for 51 weeks the first four doses of trastuzumab are given with paclitaxel. Treatments are given over a total of one year. During the study, participants will undergo screening, laboratory tests, and follow-up visits. Researchers will monitor side effects and measure disease-free survival for up to 72 months after randomization. Quality of life, symptoms, work productivity, cardiac function, and gene profiling will also be evaluated. Participants will be followed for five years after completing treatment to collect long-term data.

Age: 18Years +All GendersPhase 2
53 locations
C

Actively Recruiting

Researchers are investigating whether combining chemotherapy with the immunotherapy drug pembrolizumab improves overall survival compared to pembrolizumab alone in older adults aged 70 and above with advanced stage IIIB-IV non-small cell lung cancer. This phase III trial focuses on a vulnerable population and aims to evaluate survival, disease progression, treatment response, toxicity, quality of life, and other health factors. The study also explores how gut microbes and geriatric assessments relate to treatment outcomes. Participants are randomly assigned to one of two groups. In the first group, patients receive pembrolizumab intravenously every 21 days for four cycles, followed by maintenance doses every 21 or 42 days for up to two years if there is no disease progression or severe side effects. In the second group, patients receive pembrolizumab plus a chemotherapy regimen chosen by the investigator, given intravenously on specific schedules for four cycles, followed by the same pembrolizumab maintenance as the first group. Imaging tests like MRI, CT, and PET scans are done at the start and throughout treatment. During the study, participants undergo regular clinical assessments, imaging, and laboratory tests to monitor their cancer and overall health. Follow-up visits occur every three months for up to two years and then every six months until five years after starting treatment. Researchers measure overall survival, progression-free survival, response rates, side effects, and quality of life. The study also collects patient-reported information and evaluates safety and tolerability over time.

Age: 70Years +All GendersPhase 3
329 locations
R

Actively Recruiting

This trial investigates the use of ivonescimab compared to pembrolizumab as first-line treatments for patients with metastatic non-small cell lung cancer NSCLC whose tumors show high PD-L1 expression. The study focuses on evaluating overall survival and progression-free survival, aiming to understand how these treatments affect disease outcomes in this specific group. Participants will be randomly assigned to receive either ivonescimab or pembrolizumab as intravenous injections. Both treatments are administered as part of a double-blinded, phase 3 study, with a treatment period that may continue while monitoring the patients response and survival for up to approximately 36 months. Throughout the study, participants will undergo regular assessments including measurements of survival, disease progression, response rates, and monitoring for adverse events and laboratory abnormalities. Researchers will collect data on the duration of response and disease control, with safety follow-up continuing up to 30 to 90 days after the last treatment dose or initiation of other anticancer therapies. The overall study period extends until June 2029.

Age: 18Years +All GendersPhase 3
285 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations

1-10 of 28

1